Semaglutide produces average weight loss of 14.9% of body weight in clinical trials, far exceeding what most people achieve through diet and exercise alone
Do you often feel tired, foggy, or low on energyno matter how much you sleep
March 2026 was a turning point month for GLP-1 practices, with regulators, payers, and manufacturers all reshaping the rules at once
Help you apply for manufacturer PAPs if eligible
Dual NOX/SGLT2 inhibitors as the hybrid compound GKT137831 (inhibitor of NOX1 and NOX4) and empagliflozin (SGLT2 inhibitor) have shown synergistic effects, improving insulin sensitivity by 40% in diabetic rodent models ( Emerging strategies focus on mitochondrial-specific antioxidants (e.g., MitoQ, SS-31), which have shown promise in preclinical and early-phase clinical trials by reducing mtROS and improving endothelial function in diabetic patients (Mason et al., 2022)